4D Molecular Therapeutics, Inc. Revenue
4D Molecular Therapeutics, Inc. (FDMT) reported Revenue of $3.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. revenues for the quarter ending 2026-06-30 was $3.78M, a 25106.67% increase year-over-year.
- 4D Molecular Therapeutics, Inc. revenues for the quarter ending 2026-03-31 was $3.05M, a 21664.29% increase year-over-year.
- 4D Molecular Therapeutics, Inc. revenues for the quarter ending 2025-06-30 was $15.00K, a 200.00% increase year-over-year.
- 4D Molecular Therapeutics, Inc. revenues for the quarter ending 2025-03-31 was $14.00K, a 50.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. revenues for fiscal 2025 was $85.21M, a 230194.59% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. revenues for fiscal 2024 was $37.00K, a 99.82% decline from fiscal 2023.
- 4D Molecular Therapeutics, Inc. revenues for fiscal 2023 was $20.72M, a 562.29% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. revenues for fiscal 2022 was $3.13M, a 82.65% decline from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.78M 10-Q · filed 2026-08-13 | $6.83M 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $3.05M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $85.21M 10-K · filed 2026-03-18 | |||
| 2025-06-30 | $15.00K 10-Q · filed 2026-08-13 | $29.00K 10-Q · filed 2026-08-13 | $30.00K derived: sum of 3 quarters · filed 2026-08-13 | $33.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $14.00K 10-Q · filed 2026-05-07 | $15.00K derived: sum of 2 quarters · filed 2026-05-07 | $18.00K derived: sum of 3 quarters · filed 2026-05-07 | $23.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $4.00K derived: sum of 2 quarters · filed 2026-03-18 | $9.00K derived: sum of 3 quarters · filed 2026-03-18 | $37.00K 10-K · filed 2026-03-18 |
| 2024-09-30 | $3.00K 10-Q · filed 2024-11-13 | $8.00K derived: sum of 2 quarters · filed 2024-11-13 | $36.00K 10-Q · filed 2024-11-13 | $17.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-06-30 | $5.00K 10-Q · filed 2024-08-08 | $33.00K 10-Q · filed 2024-08-08 | $14.00K derived: sum of 3 quarters · filed 2025-02-28 | $20.22M derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-03-31 | $28.00K 10-Q · filed 2024-05-09 | $9.00K derived: sum of 2 quarters · filed 2025-02-28 | $20.21M derived: sum of 3 quarters · filed 2025-02-28 | $20.45M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $20.18M derived: sum of 2 quarters · filed 2025-02-28 | $20.42M derived: sum of 3 quarters · filed 2025-02-28 | $20.72M 10-K · filed 2025-02-28 |
| 2023-09-30 | $20.20M 10-Q · filed 2024-11-13 | $20.44M derived: sum of 2 quarters · filed 2024-11-13 | $20.74M 10-Q · filed 2024-11-13 | $21.99M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $239.00K 10-Q · filed 2024-08-08 | $538.00K 10-Q · filed 2024-08-08 | $1.78M derived: sum of 3 quarters · filed 2024-08-08 | $2.28M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $298.00K 10-Q · filed 2024-05-09 | $1.54M derived: sum of 2 quarters · filed 2024-05-09 | $2.04M derived: sum of 3 quarters · filed 2024-05-09 | $2.21M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.75M derived: sum of 2 quarters · filed 2024-02-29 | $1.91M derived: sum of 3 quarters · filed 2024-02-29 | $3.13M 10-K · filed 2024-02-29 |
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-09 | $662.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.88M 10-Q · filed 2023-11-09 | $1.97M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $162.00K 10-Q · filed 2023-08-09 | $1.38M 10-Q · filed 2023-08-09 | $1.47M derived: sum of 3 quarters · filed 2023-08-09 | $2.84M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.22M 10-Q · filed 2023-05-11 | $1.31M derived: sum of 2 quarters · filed 2023-05-11 | $2.68M derived: sum of 3 quarters · filed 2023-05-11 | $17.26M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.46M derived: sum of 2 quarters · filed 2023-03-15 | $16.04M derived: sum of 3 quarters · filed 2023-03-15 | $18.04M 10-K · filed 2023-03-15 |
| 2021-09-30 | $1.37M 10-Q · filed 2022-11-08 | $15.95M derived: sum of 2 quarters · filed 2022-11-08 | $17.95M 10-Q · filed 2022-11-08 | $16.97M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $14.58M 10-Q · filed 2022-08-11 | $16.58M 10-Q · filed 2022-08-11 | $15.60M derived: sum of 3 quarters · filed 2022-08-11 | $23.02M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-12 | $1.02M derived: sum of 2 quarters · filed 2022-05-12 | $8.44M derived: sum of 3 quarters · filed 2022-05-12 | $12.08M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$977.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $6.44M derived: sum of 2 quarters · filed 2022-03-28 | $10.08M derived: sum of 3 quarters · filed 2022-03-28 | $13.61M 10-K · filed 2022-03-28 |
| 2020-09-30 | $7.42M 10-Q · filed 2021-11-10 | $11.05M derived: sum of 2 quarters · filed 2021-11-10 | $14.59M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.63M 10-Q · filed 2021-08-12 | $7.17M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $3.54M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $6.99M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |